Behavioral Therapy Development for Methamphetamine Abusers

NCT00249678 | Withdrawn Phase 2

• 3 other identifiers: NIDA-18075-1R21DA018075R21-18075-1
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.

Conditions

The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

Keywords

Behavior Therapy; methamphetamine

Outcome Measures

Primary Outcomes (5)

• Craving

• Medication compliance

• Addiction severity

• Psychiatric interview

• Sex-risk behavior

Secondary Outcomes (2)

• Depression

• Quality of Life

Interventions

Behavior Therapy BEHAVIORAL

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
• Willing to give informed consent and comply with study procedures;
• Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
• Diagnosed with current methamphetamine abuse as determined by MINI; and
• Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

You may not qualify if:

• Unwilling to give, or withdrawal of, informed consent;
• Inability to understand nature of study;
• A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
• Current suicidal ideation or suicide attempt within the past 3 months; and
• Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
• Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.

Sponsors & Collaborators

• University of California, Los Angeles: lead
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (3)

UCLA Medical Center

Los Angeles, California, 90024, United States

Location

UCLA, Integrated Substance Abuse Programs

Los Angeles, California, 90024, United States

Location

UCLA CARE Clinic

Los Angeles, California, 90035, United States

Location

MeSH Terms

Interventions

Behavior Therapy

Intervention Hierarchy (Ancestors)

Psychotherapy; Behavioral Disciplines and Activities

Study Officials

• James Peck, Other

  University of California, Los Angeles

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Purpose: TREATMENT
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: November 3, 2005
• First Posted: November 7, 2005
• Study Start: September 1, 2004
• Primary Completion: May 1, 2007
• Study Completion: May 1, 2007
• Last Updated: February 17, 2020

Record last verified: 2020-02

Locations

US (3)